Pharma & R&D
Cancer Drug Development Hits Setback in Late-Stage Trial
By Intent.Health Team • 2 min read
What’s happening
A combination cancer therapy from Merck and Eisai failed to improve survival outcomes in a late-stage kidney cancer trial.
The treatment did not outperform existing standard therapies, missing key study goals.
What’s changing / Business impact
- Even advanced combinations of blockbuster drugs (like Keytruda-based therapies) are not guaranteed to succeed
- Late-stage failures result in significant lost revenue potential and delayed pipeline expansion
- Oncology competition remains high-risk and high-cost
Why this matters
Drug development is not linear, and most bets fail late, not early.
This shows that:
- Pharma pipelines are fragile despite strong portfolios
- Growth projections based on pipeline expansion are inherently uncertain
- Investors and buyers must track trial outcomes, not just initial approvals